Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Dermatology | Oncology | Family Medicine
Disease Category: Melanoma
Location: United States, WV

Clinical Trial Details

Overview

Research Study Summary

ECOG 1609 - A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon α-2b for Resected High-Risk Melanoma

Purpose

Objectives: To evaluate recurrence-free survival and overall survival between patients randomized to receive post-operative adjuvant ipilimumab versus those randomized to receive high-dose interferon.

To Learn more
Phase

3

Gender

Both Male and Female

Age

N/A

Overall Status

Recruiting

Facility Type

N/A

Contact

West Virginia University - Clinical Trials Research Unit
Loacted In:
Morgantown, WV 26506

View Map

CW ID: 181679

Date Last Changed: July 18, 2013


DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.